 Jennifer Taylor-Cousar
Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 45 | 2021 | 770 | 11.030 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 28 | 2021 | 207 | 8.550 |
Why?
| | Quinolones | 16 | 2021 | 84 | 7.180 |
Why?
| | Aminophenols | 18 | 2021 | 62 | 7.170 |
Why?
| | Benzodioxoles | 14 | 2021 | 49 | 5.500 |
Why?
| | Chloride Channel Agonists | 12 | 2021 | 33 | 3.030 |
Why?
| | Aminopyridines | 5 | 2018 | 75 | 2.660 |
Why?
| | Indoles | 10 | 2021 | 345 | 2.650 |
Why?
| | Membrane Transport Modulators | 3 | 2020 | 10 | 2.420 |
Why?
| | Drug Combinations | 15 | 2021 | 281 | 1.810 |
Why?
| | Respiratory System Agents | 2 | 2020 | 15 | 1.490 |
Why?
| | Pyrazoles | 8 | 2021 | 337 | 1.360 |
Why?
| | Pregnancy Complications | 2 | 2020 | 471 | 1.040 |
Why?
| | Pyrrolidines | 5 | 2021 | 40 | 1.030 |
Why?
| | Reproductive Health | 3 | 2021 | 47 | 0.990 |
Why?
| | Pyridines | 6 | 2021 | 465 | 0.980 |
Why?
| | Mutation | 12 | 2021 | 3257 | 0.920 |
Why?
| | Paranasal Sinuses | 2 | 2020 | 54 | 0.910 |
Why?
| | Ape Diseases | 2 | 2021 | 7 | 0.900 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 22 | 0.890 |
Why?
| | Compassionate Use Trials | 1 | 2019 | 7 | 0.850 |
Why?
| | Aerosols | 1 | 2020 | 166 | 0.820 |
Why?
| | Drug Monitoring | 6 | 2020 | 217 | 0.810 |
Why?
| | Drug Approval | 1 | 2019 | 72 | 0.800 |
Why?
| | Lung | 7 | 2020 | 3515 | 0.750 |
Why?
| | Sputum | 4 | 2019 | 273 | 0.750 |
Why?
| | Pseudomonas aeruginosa | 8 | 2019 | 280 | 0.740 |
Why?
| | Pseudomonas Infections | 7 | 2019 | 171 | 0.730 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 213 | 0.720 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2017 | 43 | 0.690 |
Why?
| | Breast Feeding | 1 | 2020 | 332 | 0.680 |
Why?
| | Rifampin | 1 | 2017 | 67 | 0.670 |
Why?
| | Pongo abelii | 1 | 2016 | 2 | 0.660 |
Why?
| | Azithromycin | 5 | 2019 | 67 | 0.660 |
Why?
| | Adult | 28 | 2021 | 31401 | 0.630 |
Why?
| | Glucose Intolerance | 1 | 2016 | 123 | 0.630 |
Why?
| | Glucose Tolerance Test | 1 | 2016 | 379 | 0.620 |
Why?
| | Sildenafil Citrate | 2 | 2014 | 54 | 0.610 |
Why?
| | Forced Expiratory Volume | 9 | 2019 | 526 | 0.600 |
Why?
| | Bronchiectasis | 1 | 2016 | 96 | 0.600 |
Why?
| | Sinusitis | 2 | 2016 | 153 | 0.590 |
Why?
| | Treatment Outcome | 13 | 2021 | 8908 | 0.590 |
Why?
| | Tobramycin | 5 | 2019 | 40 | 0.590 |
Why?
| | Humans | 48 | 2021 | 109040 | 0.580 |
Why?
| | Leukocyte Elastase | 1 | 2014 | 84 | 0.580 |
Why?
| | Biomedical Research | 1 | 2020 | 595 | 0.570 |
Why?
| | Sweat | 7 | 2021 | 43 | 0.500 |
Why?
| | Anti-Bacterial Agents | 8 | 2019 | 1278 | 0.450 |
Why?
| | Quinolines | 2 | 2021 | 121 | 0.430 |
Why?
| | Female | 31 | 2021 | 61540 | 0.430 |
Why?
| | Hypoventilation | 1 | 2009 | 8 | 0.410 |
Why?
| | Drug Interactions | 4 | 2020 | 454 | 0.410 |
Why?
| | Respiratory Muscles | 1 | 2009 | 30 | 0.410 |
Why?
| | ABO Blood-Group System | 1 | 2009 | 26 | 0.400 |
Why?
| | Homozygote | 3 | 2018 | 192 | 0.400 |
Why?
| | Diabetes Mellitus | 1 | 2016 | 877 | 0.390 |
Why?
| | Blood Glucose | 2 | 2016 | 1779 | 0.370 |
Why?
| | Male | 29 | 2021 | 60099 | 0.370 |
Why?
| | Adolescent | 15 | 2021 | 18184 | 0.360 |
Why?
| | Needs Assessment | 2 | 2020 | 332 | 0.360 |
Why?
| | Respiratory Function Tests | 3 | 2018 | 581 | 0.330 |
Why?
| | Child | 10 | 2021 | 16571 | 0.320 |
Why?
| | Young Adult | 13 | 2021 | 10678 | 0.320 |
Why?
| | Double-Blind Method | 6 | 2021 | 1690 | 0.320 |
Why?
| | Pregnancy Outcome | 2 | 2020 | 344 | 0.320 |
Why?
| | Quality of Life | 4 | 2021 | 1968 | 0.320 |
Why?
| | Pregnancy | 4 | 2021 | 5004 | 0.300 |
Why?
| | Polymorphism, Genetic | 1 | 2009 | 787 | 0.290 |
Why?
| | C-Reactive Protein | 2 | 2018 | 360 | 0.270 |
Why?
| | Patient Selection | 2 | 2019 | 687 | 0.270 |
Why?
| | Tomography, X-Ray Computed | 3 | 2021 | 2383 | 0.240 |
Why?
| | Pongo pygmaeus | 1 | 2021 | 7 | 0.240 |
Why?
| | Chlorides | 5 | 2021 | 131 | 0.230 |
Why?
| | Women's Rights | 1 | 2020 | 6 | 0.220 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2256 | 0.220 |
Why?
| | Disease Progression | 5 | 2020 | 2433 | 0.220 |
Why?
| | Virulence Factors | 2 | 2014 | 132 | 0.210 |
Why?
| | Communicable Disease Control | 1 | 2020 | 70 | 0.210 |
Why?
| | Aztreonam | 2 | 2016 | 7 | 0.210 |
Why?
| | Pregnancy, Unplanned | 1 | 2020 | 33 | 0.210 |
Why?
| | Colistin | 1 | 2019 | 9 | 0.210 |
Why?
| | Sexism | 1 | 2020 | 36 | 0.210 |
Why?
| | International Cooperation | 1 | 2020 | 175 | 0.200 |
Why?
| | Prospective Studies | 4 | 2019 | 5930 | 0.200 |
Why?
| | Medication Therapy Management | 1 | 2020 | 67 | 0.200 |
Why?
| | Receptors, Interleukin-8B | 1 | 2018 | 22 | 0.200 |
Why?
| | Contraception Behavior | 1 | 2020 | 88 | 0.200 |
Why?
| | Neutrophils | 3 | 2016 | 1177 | 0.200 |
Why?
| | Genotype | 6 | 2021 | 2072 | 0.200 |
Why?
| | Contraception | 1 | 2020 | 98 | 0.190 |
Why?
| | Respiratory Tract Infections | 1 | 2021 | 255 | 0.190 |
Why?
| | Machine Learning | 1 | 2020 | 212 | 0.180 |
Why?
| | Pregnancy, High-Risk | 1 | 2017 | 12 | 0.180 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 5 | 0.180 |
Why?
| | Leukocytes | 1 | 2018 | 276 | 0.170 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 182 | 0.170 |
Why?
| | Pregnancy Rate | 1 | 2017 | 45 | 0.170 |
Why?
| | Biphenyl Compounds | 1 | 2017 | 41 | 0.170 |
Why?
| | Biological Availability | 1 | 2017 | 178 | 0.170 |
Why?
| | Alleles | 4 | 2021 | 897 | 0.170 |
Why?
| | Risk Adjustment | 1 | 2017 | 76 | 0.170 |
Why?
| | Research | 1 | 2020 | 441 | 0.160 |
Why?
| | Recovery of Function | 1 | 2020 | 607 | 0.160 |
Why?
| | Interferons | 1 | 2016 | 120 | 0.160 |
Why?
| | Pilot Projects | 2 | 2020 | 1390 | 0.160 |
Why?
| | Albuterol | 1 | 2016 | 95 | 0.160 |
Why?
| | Pharmacogenetics | 1 | 2017 | 161 | 0.160 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1632 | 0.150 |
Why?
| | Staphylococcal Infections | 1 | 2019 | 325 | 0.150 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 483 | 0.150 |
Why?
| | Middle Aged | 9 | 2021 | 28504 | 0.150 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2014 | 35 | 0.150 |
Why?
| | Metalloproteases | 1 | 2014 | 30 | 0.150 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 992 | 0.140 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 419 | 0.140 |
Why?
| | Severity of Illness Index | 4 | 2018 | 2801 | 0.140 |
Why?
| | Diabetes Complications | 1 | 2016 | 250 | 0.140 |
Why?
| | Bronchodilator Agents | 1 | 2016 | 246 | 0.140 |
Why?
| | Quorum Sensing | 1 | 2014 | 78 | 0.140 |
Why?
| | Risk Assessment | 2 | 2020 | 3075 | 0.140 |
Why?
| | Genetic Predisposition to Disease | 2 | 2015 | 2368 | 0.130 |
Why?
| | Wound Infection | 1 | 2013 | 30 | 0.130 |
Why?
| | Health Services Accessibility | 1 | 2019 | 747 | 0.130 |
Why?
| | Animals | 6 | 2021 | 34587 | 0.130 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2016 | 358 | 0.130 |
Why?
| | Neutrophil Activation | 1 | 2013 | 106 | 0.120 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 64 | 0.120 |
Why?
| | Precision Medicine | 1 | 2015 | 278 | 0.120 |
Why?
| | Cellular Structures | 1 | 2011 | 3 | 0.120 |
Why?
| | Mycobacterium | 1 | 2013 | 97 | 0.120 |
Why?
| | Comorbidity | 1 | 2016 | 1577 | 0.120 |
Why?
| | Microbial Viability | 1 | 2011 | 73 | 0.110 |
Why?
| | Extracellular Space | 1 | 2011 | 151 | 0.110 |
Why?
| | Drug Therapy, Combination | 3 | 2021 | 1021 | 0.110 |
Why?
| | Patient Admission | 1 | 2012 | 194 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 1 | 2013 | 489 | 0.110 |
Why?
| | Burns | 1 | 2013 | 190 | 0.110 |
Why?
| | Biomarkers | 3 | 2018 | 3364 | 0.110 |
Why?
| | Survival Rate | 2 | 2018 | 1820 | 0.100 |
Why?
| | Body Mass Index | 1 | 2017 | 2071 | 0.100 |
Why?
| | Mass Screening | 1 | 2016 | 987 | 0.100 |
Why?
| | Infant, Newborn | 1 | 2020 | 4852 | 0.100 |
Why?
| | Inpatients | 1 | 2012 | 310 | 0.100 |
Why?
| | Blood Group Antigens | 1 | 2009 | 18 | 0.100 |
Why?
| | Mucus | 1 | 2009 | 52 | 0.100 |
Why?
| | ADP Ribose Transferases | 1 | 2007 | 12 | 0.090 |
Why?
| | Furin | 1 | 2007 | 8 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 4370 | 0.090 |
Why?
| | Exotoxins | 1 | 2007 | 16 | 0.090 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2007 | 17 | 0.090 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2009 | 156 | 0.090 |
Why?
| | Cyclic GMP | 1 | 2007 | 138 | 0.090 |
Why?
| | Phenotype | 1 | 2015 | 2968 | 0.090 |
Why?
| | Retrospective Studies | 6 | 2021 | 10614 | 0.090 |
Why?
| | Bacterial Toxins | 1 | 2007 | 109 | 0.090 |
Why?
| | Survivors | 1 | 2010 | 366 | 0.080 |
Why?
| | Sulfones | 1 | 2007 | 98 | 0.080 |
Why?
| | Respiratory System | 1 | 2007 | 139 | 0.080 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2598 | 0.080 |
Why?
| | Respiratory Mucosa | 1 | 2007 | 244 | 0.080 |
Why?
| | Administration, Inhalation | 2 | 2019 | 646 | 0.070 |
Why?
| | Respiration, Artificial | 1 | 2009 | 549 | 0.070 |
Why?
| | Piperazines | 1 | 2007 | 308 | 0.070 |
Why?
| | United States | 2 | 2020 | 11613 | 0.070 |
Why?
| | RNA, Messenger | 1 | 2013 | 2883 | 0.070 |
Why?
| | Aged | 3 | 2021 | 19745 | 0.070 |
Why?
| | Inflammation | 1 | 2014 | 2277 | 0.070 |
Why?
| | Logistic Models | 2 | 2019 | 2013 | 0.070 |
Why?
| | Cell Separation | 2 | 2016 | 305 | 0.060 |
Why?
| | Microbial Sensitivity Tests | 2 | 2014 | 288 | 0.060 |
Why?
| | Biofilms | 2 | 2014 | 232 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 2017 | 0.060 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2020 | 27 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2012 | 1865 | 0.050 |
Why?
| | Tetraspanin 30 | 1 | 2018 | 9 | 0.050 |
Why?
| | Condoms | 1 | 2020 | 113 | 0.050 |
Why?
| | Administration, Intravenous | 1 | 2019 | 138 | 0.050 |
Why?
| | British Columbia | 1 | 2018 | 11 | 0.050 |
Why?
| | trans-Golgi Network | 2 | 2007 | 12 | 0.050 |
Why?
| | Registries | 2 | 2020 | 1738 | 0.050 |
Why?
| | Morbidity | 1 | 2018 | 247 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2016 | 3323 | 0.040 |
Why?
| | Drug Administration Routes | 1 | 2016 | 47 | 0.040 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2007 | 172 | 0.040 |
Why?
| | Gene Deletion | 1 | 2018 | 395 | 0.040 |
Why?
| | Leadership | 1 | 2020 | 283 | 0.040 |
Why?
| | Genetic Variation | 1 | 2021 | 986 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2018 | 4340 | 0.040 |
Why?
| | Interferon-alpha | 1 | 2016 | 203 | 0.040 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2014 | 67 | 0.040 |
Why?
| | Colorado | 2 | 2018 | 4509 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 858 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1044 | 0.030 |
Why?
| | Medication Adherence | 1 | 2018 | 512 | 0.030 |
Why?
| | Rhinitis | 1 | 2014 | 108 | 0.030 |
Why?
| | Ciprofloxacin | 1 | 2013 | 24 | 0.030 |
Why?
| | Survival Analysis | 1 | 2016 | 1413 | 0.030 |
Why?
| | Superoxides | 1 | 2013 | 241 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1596 | 0.030 |
Why?
| | Drug Synergism | 1 | 2013 | 367 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 372 | 0.030 |
Why?
| | Suspensions | 1 | 2011 | 32 | 0.030 |
Why?
| | Risk Factors | 2 | 2016 | 8780 | 0.030 |
Why?
| | Enteral Nutrition | 1 | 2012 | 139 | 0.030 |
Why?
| | Cell Line | 2 | 2007 | 2967 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2011 | 447 | 0.030 |
Why?
| | Prognosis | 1 | 2018 | 3443 | 0.030 |
Why?
| | Insulin Infusion Systems | 1 | 2012 | 275 | 0.030 |
Why?
| | Age Distribution | 1 | 2010 | 391 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 389 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 6708 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2018 | 4820 | 0.020 |
Why?
| | Age of Onset | 1 | 2010 | 501 | 0.020 |
Why?
| | Chronic Disease | 1 | 2014 | 1649 | 0.020 |
Why?
| | Epithelial Sodium Channels | 1 | 2007 | 15 | 0.020 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2007 | 23 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1997 | 0.020 |
Why?
| | Guanylate Cyclase | 1 | 2007 | 39 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2007 | 78 | 0.020 |
Why?
| | Ion Transport | 1 | 2007 | 67 | 0.020 |
Why?
| | Purines | 1 | 2007 | 151 | 0.020 |
Why?
| | Sodium | 1 | 2007 | 201 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 7082 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 586 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2007 | 1282 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2012 | 932 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2007 | 462 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2010 | 619 | 0.020 |
Why?
| | Mice | 2 | 2013 | 14929 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2013 | 3843 | 0.020 |
Why?
| | Insulin | 1 | 2012 | 2070 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2007 | 890 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2139 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2007 | 999 | 0.010 |
Why?
| | Macrophages | 1 | 2007 | 1188 | 0.010 |
Why?
| | Signal Transduction | 1 | 2007 | 4839 | 0.010 |
Why?
|
|
Taylor-Cousar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|